Home > Insider Trading > Filing (0001209191-18-044804)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1604464	Atara Biotherapeutics Inc.	ATRA	Biological Products, (No Disgnostic Substances) (2836)	460920988

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1702457	Joe Newell	C/O Atara Biotherapeutics, Inc. 611 Gateway Blvd., Suite 900 South San Francisco CA 94080	Chief Tech. Operations Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-08-01	1,500	$20.40	33,358	No	4	M	Direct
Common Stock	Disposition	2018-08-01	1,000	$37.09	32,358	No	4	S	Direct
Common Stock	Disposition	2018-08-01	100	$37.65	32,258	No	4	S	Direct
Common Stock	Disposition	2018-08-01	300	$39.05	31,958	No	4	S	Direct
Common Stock	Disposition	2018-08-01	100	$40.40	31,858	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-08-01	1,500	$0.00	1,500	$20.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
78,500		2024-04-03	No	4	M	Direct

Footnotes

Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.50 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.70 to $39.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service.